BioSpace News Archive

Although the lawsuits over who owns the rights to gene editing technique CRISPR seemed to be mostly settled in September 2018, a recent dispute between the University of California and the Cambridge, Massachusetts-based Broad Institute suggested the battles aren’t done yet.

Singapore scientists and clinicians have discovered a promising use of antibodies to target a new cancer antigen, as an alternative for chemotherapy

Cristal Therapeutics announces that Dr Werner Cautreels is joining the Company’s supervisory board taking on the role of Chairman.

Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology

Ultragenyx Pharmaceutical Inc. announced that it has submitted to the U.S. Food and Drug Administration a New Drug Application for UX007 for the treatment of long-chain fatty acid oxidation disorders, a group of genetic disorders in which the body is unable to convert long-chain fatty acids into energy.

Supporting rare disease diagnosis, education, and clinical research

Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents.

Almac Clinical Services, part of the global contract pharmaceutical development and manufacturing organization the Almac Group, is delighted to invite participants from the Biopharma industry to join its Souderton Lunch and Learn Workshop on Wednesday, September 18.

Researchers with Johns Hopkins Kimmel Cancer Center recently published research that followed 270 cancer patients treated with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab). The research reported impressive improvements in five-year survival rates.

Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.